News

Vibrent Health Integrates Electronic Health Records into its Digital Research Platform, Empowering Participants to Share Their Data for Clinical Research

New framework based on HL7 Fast Healthcare Interoperability Resources (FHIR) gives Standards based access to EHR data to accelerate clinical research and digital trials

FAIRFAX, Va. — Vibrent Health, a health technology startup powering the future of precision health research, announced the integration of electronic health record (EHR) data into its Digital Health Solutions Platform, a platform that enables collection of health data from broad sources including biospecimens, genomics, environment, lifestyle and behavior, and wearable device data for clinical research and trials. Vibrent Health supports leading FHIR-enabled EHR vendors such as Epic and Cerner to ensure that their systems are seamlessly interoperable with the DHS Platform. 

Access to EHR data removes barriers to health research and offers researchers valuable insight,” explained Mark Begale, vice president, Vibrent Health. “Transparent, secure access to the full history of a participant’s medical record is key to gathering whole-person data which is essential to advancing precision medicine.”

Vibrent Health’s EHR integration tools were developed to support the National Institutes of Health’s 10-year, million-person All of Us Research Program, for which Vibrent Health serves as the Participant Technology Systems Center. 

When a health research participant consents to sharing their EHR for research, Vibrent Health’s EHR tools enable researchers to access a wealth of health data via the DHS Platform.  This data can include information about diagnoses, treatments, medications, lab results and other health-related information that can provide a fuller and more accurate picture of a research participant’s health than data that is collected by researchers manually.

“Our platform’s EHR integration is built using the emerging standard of HL7 Fast Healthcare Interoperability Resources (FHIR) to give researchers the ability to access clinical records of various participants and combine that data with other data sources,” said Vibrent Health CEO Praduman “PJ” Jain. “Reusing data collected from participants’ clinical visits to health care providers helps to improve patient participation and provides the real-world evidence needed to accelerate health research.”

A major step to transformative precision medicine research, using EHR data in clinical research has the potential to bring new therapies to patients sooner and at lower cost. Access to data promises to improve safety, patient-centeredness, communication, education and equity. 

“We regularly hear from researchers that they want to access this critical data, but the costs are simply too high. Easier access to EHR integration could be the key to making a scientific discovery,” said Begale.

Recent News

02/09/2026

Activation Capital Expands Frontier BioHealth and Strengthens its Continuum of Support for Life Sciences Founders

Activation Capital today announced enhancements to Frontier BioHealth, building on the program’s successful 2024 launch and inaugural cohort while reinforcing its broader continuum of life sciences entrepreneurship programs designed to help science-driven companies progress toward commercialization and investor readiness. Frontier BioHealth was created to address a critical gap facing emerging biohealth founders: access to practical

02/04/2026

Governor Spanberger Announces Expansion of Paid Internship Opportunities with Virginia Businesses

Governor Abigail Spanberger today launched InternshipsVA, a new statewide program to help Virginia employers design and launch high-quality, paid internships for higher education students in Virginia. The Commonwealth has committed $14.5 million each year to support this program. The Governor was joined by leaders of the Virginia Chamber of Commerce, the Virginia Economic Development Partnership

02/03/2026

SSI Diagnostica Group Acquires InDevR

SSI Diagnostica Group, a global company specializing in testing solutions for infectious diseases, has announced the acquisition of InDevR, a Colorado-based provider of advanced multiplexed solutions for vaccine testing and quality control. The addition strengthens SSID Group’s leadership in pneumococcal vaccine QC testing with next-generation multiplexing assays and enhanced customization capabilities. InDevR will advance the Group’s offering by